SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).

Trial Details

NCT ID
NCT04923126
Phase
PHASE1 / PHASE2
Sponsor
St. Jude Children's Research Hospital
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Mirdametinib
Locations (sample)
  • Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

  • Participants with histologically confirmed or suspected low-grade glioma, including neuronal and mixed neuronal-glial tumors
  • Participant must have adequate tumor tissue from primary and/or relapsed tumor for central pathology review
  • For Phase 1: Projected to be ≥ 2 years and \< 25 years at the time of study enrollment
  • Participant's body surface area (BSA) at time of study enrollment must fall within the range outlined in the protocol for the specific dose level u…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →